The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

December 31, 2026

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

LM-302+Candonilimab+Capecitabine

LM-302: 1.8mg/kg ivgtt d1, q2w; Canonilimab: 6mg/kg ivgtt d1, q2w; Capecitabine: 1000mg/m\^2 po bid d1-10, q2w.

Trial Locations (1)

RECRUITING

Zhongshan Hospital Fudan University, Shanghai

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER